Neetu Dayal
Overview
Explore the profile of Neetu Dayal including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
26
Citations
109
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Chaudhuri R, Dayal N, Kaiser J, Mohallem R, Brauer N, Yeboah K, et al.
Bioorg Chem
. 2025 Mar;
159:108298.
PMID: 40081260
Therapeutic options for aggressive cancer types such as breast and lung remain limited; disease relapse and death occur in 30-60% of non-small cell lung cancer (NSCLC) patients, whereas in triple-negative...
2.
Dayal N, Chaudhuri R, Yeboah K, Brauer N, Sintim H
Pharmaceuticals (Basel)
. 2025 Jan;
17(12.
PMID: 39770502
The protein kinases CLK and ROCK play key roles in cell growth and migration, respectively, and are potential anticancer targets. ROCK inhibitors have been approved by the FDA for various...
3.
Ramdas B, Dayal N, Pandey R, Larocque E, Kanumuri R, Pasupuleti S, et al.
J Clin Invest
. 2024 Jul;
134(12).
PMID: 38950330
Activating mutations of FLT3 contribute to deregulated hematopoietic stem and progenitor cell (HSC/Ps) growth and survival in patients with acute myeloid leukemia (AML), leading to poor overall survival. AML patients...
4.
Dilday T, Abt M, Ramos-Solis N, Dayal N, Larocque E, Oblak A, et al.
Cell Chem Biol
. 2024 Feb;
31(5):989-999.e7.
PMID: 38307028
Human epidermal growth factor receptor 2 (HER2)-targeted agents have proven to be effective, however, the development of resistance to these agents has become an obstacle in treating HER2+ breast cancer....
5.
Akwata D, Kempen A, Lamptey J, Dayal N, Brauer N, Sintim H
RSC Med Chem
. 2024 Jan;
15(1):178-192.
PMID: 38283221
Current treatment options for patients with multiple myeloma (MM) include proteasome inhibitors, anti-CD38 antibodies, and immunomodulatory agents. However, if patients have continued disease progression after administration of these treatments, there...
6.
Akwata D, Kempen A, Dayal N, Brauer N, Sintim H
ChemMedChem
. 2023 Nov;
19(1):e202300442.
PMID: 37971283
FLT3 is mainly expressed in immune and various cancer cells and is a drug target for acute myeloid leukemia (AML). Recently, FLT3 has also been identified as a potential target...
7.
Ong W, Dayal N, Chaudhuri R, Lamptey J, Sintim H
RSC Med Chem
. 2023 Jun;
14(6):1101-1113.
PMID: 37360395
The cGAS-STING axis plays an important role in protecting higher organisms against invading pathogens or cancer by promoting the production of cytokines and interferons. However, persistent or uncontrolled activation of...
8.
Khatri U, Dayal N, Hu X, Larocque E, Naganna N, Shen T, et al.
Mol Cancer Ther
. 2023 Apr;
22(6):717-725.
PMID: 37070927
Selpercatinib (LOXO292) and pralsetinib (BLU667) are RET protein tyrosine kinase inhibitors (TKIs) recently approved for treating RET-altered cancers. However, RET mutations that confer selpercatinib/pralsetinib resistance have been identified, necessitating development...
9.
Onyedibe K, Nemeth A, Dayal N, Smith R, Lamptey J, Ernst R, et al.
ACS Infect Dis
. 2023 Jan;
9(2):283-295.
PMID: 36651182
Colistin, typically viewed as the antibiotic of last resort to treat infections caused by multidrug-resistant (MDR) Gram-negative bacteria, had fallen out of favor due to toxicity issues. The recent increase...
10.
Karanja C, Naganna N, Abutaleb N, Dayal N, Onyedibe K, Aryal U, et al.
Molecules
. 2022 Aug;
27(16).
PMID: 36014324
A new class of alkynyl isoquinoline antibacterial compounds, synthesized via Sonogashira coupling, with strong bactericidal activity against a plethora of Gram-positive bacteria including methicillin- and vancomycin-resistant strains is presented. HSN584...